Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Investment Group
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 02, 2020
The financing guarantees the Company's substantiated funding to advance Phase 2 clinical trials for the treatment of PTSD and other anxiety and stress-related disorders for its lead compound, BNC210.